Application of HGF-Based Liver Injury Repair in TACE Treatment for Hepatocellular Carcinoma

Abstract

Trans arterial chemoembolization (TACE) is a widely used interventional therapy for hepatocellular carcinoma (HCC) which combines localized chemotherapy and embolization to block tumor blood supply while delivering chemotherapeutic agents directly to tumor cells. It reduces tumor volume, and prolongs patient survival. However, it may cause acute liver injury due to ischemic insult and chemotherapeutic toxicity. To preserve structural integrity failure rapid restoration of hepatocyte function post-TACE and inhibition of fibrosis in non-tumor liver tissue is of great importance. Currently, no standardized treatment exists for TACE-induced liver damage, and symptom-based whose effects are limited. This study explores the therapeutic potential of hepatocyte growth factor (HGF) in promoting liver repair post-TACE. HGF, secreted primarily by Kupffer and stellate cells, binds to the c-Met receptor, activating key pathways such as ERK and AKT, which drive hepatocyte proliferation and suppress fibrogenesis. Exogenous HGF enhances regenerative processes while synergizing with cytokines such as EGF, VEGF, and IL-6. Preclinical evidence supports its role in improving liver regeneration rates. Although HGF poses potential pro-tumor risks, combination strategies with c-Met inhibitors or timed sequential administration may mitigate oncogenic signaling. Thus, adjunctive HGF therapy represents a promising approach to facilitate liver recovery after TACE.